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Background:  The intrathecal (IT) GABAA receptor antagonist, bicuculline (BIC), results in tactile allodynia (TA) 
through disinhibition in the spinal cord.  Such disinhibition is considered to be an important mechanism for 
neuropathic pain.  Agmatine, an endogenous polyamine, has a neuro-protective effect in the central nervous 
system.  We investigated the analgesic effects and mechanisms of agmatine action on BIC-induced TA.
Methods:  Male Sprague-Dawley rats, weighting 250−300 g, were subjected to implantations of PE-10 into 
the lumbar subarachnoid space for IT drug injection.  Five days after surgery, either 10μl of normal saline (NS) 
or agmatine (30μg or 10μg) in 10μl NS were injected 10 min prior to BIC (10μg) or NMDA (5μg).  We assessed 
the degree of TA (graded 0: no response, 1: mild response, 2: moderate response, 3: strong response) every 
5 min for 30 min.  Areas under curves and degree of TA were expressed as mean ± SEM.  Results were analyzed 
using one-way ANOVA followed by a Tukey test for multiple comparisons.  P ＜ 0.05 was considered significant.
Results:  IT BIC-induced strong TA reached its peak and plateaued between 10 to 15 min.  IT NS-NMDA 
induced mild transient TA for up to 15 min.  Preemptive IT AG attenuated IT BIC-induced TA dose dependently 
and preemptive IT AG10 completely abolished the IT NMDA-induced TA. 
Conclusions:  Preemptive IT AG attenuated the IT BIC-induced TA through inhibitory actions on postsynaptic 
NMDA receptor activation.  AG might be a viable therapeutic option in the treatment of neuropathic pain.  (Korean 
J Pain 2008; 21: 173-178)
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INTRODUCTION
Peripheral nerve injury can produce a persistent pain state 
characterized by spontaneous pain, painful responses to 
normally innocuous stimuli (allodynia) and augmented pain 
states against normally nociceptive stimuli (hyperalgesia). 
One of the physiological and biological mechanisms of 
neuropathic pain, that is pain initiated or caused by a primary 
lesion or dysfunction in the nervous system, is loss or 
dysfunction of the inhibitory system (disinhibition) in the 
spinal cord dorsal horn.1-3) Intrathecal (IT) administration of 
glycine or GABAA receptor antagonists (strychnine: STR, 
bicuculline: BIC, respectively) resulted in disinhibition in the 
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spinal cord and touch evoked allodynia which is an organized 
agitation response to light tactile stimulation.4,5) 
Aβ primary afferent fibers synapse to postsynaptic 
membranes and their transmissions are modulated by 
GABA releasing interneurons. IT BIC inhibits GABAA 
receptors on the presynaptic and postsynaptic membrane 
and increases the responses to Aβ inputs of normally 
innocuous stimuli.5,6) BIC and STR-induced allodynia were 
depressed by IT NMDA receptor antagonists. The order of 
activity was MK-801, AP-5, kynurenic acid, SKF10047 
and ketamine.4) IT NMDA also result in well defined 
hyperalgesia and allodynia.6) While IT BIC and STR alone 
evoked a transient spinal release of glutamate, STR did not 
affect spinal neurotransmitter release at any time and both 
allodynic effects were blocked with adenosine A1 receptor 
agonist and NMDA receptor antagonist.7,8) These findings 
suggest that IT BIC induces disinhibition of GABAergic 
inhibition of presynaptic glutamate release and postsynaptic 
NMDA receptor-nitric oxide synthase (NOS) pathway, both 
of which are crucial to inducing central sensitization and 
tactile allodynia.8)
Agmatine is an endogenous polyamine produced by 
decarboxylation of arginine, and has been shown to anta-
gonize the NMDA receptor9-11) and inhibit NOS.12-14) Recent 
neuropharmacological studies have shown that exogenous 
agmatine protects against cell damage induced by glu-
tamate and NMDA in cultured neurons.9,11) It also prevents 
or reverses biological phenomena dependent on glutamatergic 
pathways in the spinal cord (central nervous system, CNS).15) 
In the present study, we aimed to investigate the analgesic 
effects, and their mechanisms of agmatine action in a 
GABAA receptor antagonist induced allodynia rat model. 
MATERIALS AND METHODS
This study was performed with approval from the 
Institutional Animal Care and Use Committee and our 
study complied with the NIH Guide for the Care and Use 
of Laboratory Animals. The experiments were performed 
on male Sprague-Dawley rats weighting 250−300 g. 
Animals were housed in groups of 3 in plastic cages under 
a standard 12 h light/12 h dark cycle in a room maintained 
at 23 ± 3 °C. The rats were kept for at least 3 days under 
these conditions before surgery.
1. IT Catheter Implantation
Rats were implanted with a PE-10 catheter for intrathecal 
(IT) drug injection using the method described by Yaksh 
and Rudy.16) A PE-10 catheter was inserted through an 
incision in the cisternal membrane and the caudal end was 
passed into the lumbar enlargement whilst the rostral tip 
of the catheter was tunneled and fixed under the scalp for 
drug administration. Rats with neurological dysfunction 
were sacrificed. Drug experiments were initiated at least 
5 days after the implantation operation.
2. IT Drug Injection
All the drugs were dissolved in 10μl of normal saline. 
Either BIC hydrochloride (Sigma, USA) 10μg or NMDA 
(Sigma, USA) 5μg were used for induction of tactile 
allodynia. Agmatine sulfate salt (Sigma, USA) was used 
to facilitate and antiallodynic effect. Normal saline (NS 
group, n = 7) and agmatine 10μg (AG30 group, n = 7) 
or 30μg (AG30 group, n = 7) were IT administered 10 
min before BIC or NMDA IT injection. All drugs were 
flushed into the subarachnoid spaces by another 10μl of 
normal saline.
3. Measurement of Tactile Allodynia
The behavioral responses to touching hair on the lumbar 
dermatome were evaluated before and then every 5 min for 
30 min after IT drug injection. A bundle of 3 pencils was 
briefly dragged along the flank of a rat in a rostral 
direction from the buttock 5 times per subject.4,6) The 
responses of the rats (touch evoked agitation, TEA) were 
graded according to a 4 point score scale assessment as 
follows, 0: no response, I: less than 5 responses against 5 
tactile stimuli, II: 5 mild responses against 5 tactile stimuli, 
III: 5 strong responses (such as body twisting, severe 
scratching, or attempted escape from the stimuli) against 
tactile stimuli.
4. Statistics
For statistical analyses, we employed a one-way ANOVA 
followed by Tukey test for multiple comparisons. All the 
data is presented as mean ± SEM.
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Fig. 1. Time course changes in the degree of touch evoked 
agitation (tactile allodynia score) assessed on a 4 point pain scale.
Preemptive IT agmatine 10μg (AG10-BIC) and 30μg (AG30-BIC) 
dose dependently attenuated the bicuculline (NS-BIC) induced 
tactile allodynia. (*P ＜ 0.01 vs NS-BIC, †P ＜ 0.05 vs NS-BIC,
‡P ＜ 0.01 vs AG10-BIC, ). Each curve represents mean ± SEM
bar of n = 6−7 for each time point.
Fig. 2. Comparison of the areas under curves (AUC) of NS 
(NS-BIC), AG30 (agmatine 30μg-BIC) and AG10 (agmatine 10μ
g-BIC) groups. Agmatine significantly attenuated, in a dose 
dependent manner, the bicuculline (NS-BIC) induced tactile 
allodynia. Each bar is the mean ± SEM of n = 6−7 for each 
group.
Fig. 3. Comparison of the areas under curves (AUC) of NMDA 
(NS-NMDA 5μg) and AG10 (agmatine 10μg-NMDA 5μg) 
groups. Agmatine 10μg significantly attenuated the NMDA 5μg 
induced tactile allodynia. Each bar is the mean ± SEM of n = 
5 for each group.
RESULTS
The administration of a vehicle (normal saline) and 
agmatine alone had no effect on general behavior, and 
there was no TEA. In contrast, the NS group (IT NS-BIC 
10μg) showed prominent and comparable responses to 
tactile stimuli. The peak effect of BIC appeared at the 10 
min mark and plateaued until 15 min after IT injection 
(Fig. 1). However, IT NS-NMDA only transiently induced 
mild TEA for 15 min after IT injection (data not shown).
Thirtyμg of preemptive IT agmatine (AG30 group) 
significantly attenuated the BIC-induced TEA for 25 min 
after IT BIC injection (P ＜ 0.05). Preemptive IT agmatine 
10μg (AG10 group) had no effect on BIC-induced TEA. 
The mean (± SEM) areas under curves were 14.1 (± 
0.5), 7.2 (± 0.4) and 11.4 (± 0.7) in the NS, AG30 and 
AG10 groups, respectively, and there were statistically 
significant differences between the NS group and AG30 
group (P ＜ 0.01), between the NS group and AG10 group 
(P ＜ 0.05) and between the AG30 group and AG10 group 
(P ＜ 0.01) (Fig. 2).
10μg of preemptive IT agmatine completely abolished 
the TEA induced by 5μg of NMDA. The areas under the 
curves were 9 and 1 in the IT NS-NMDA and preemptive 
AG10 with NMDA groups, respectively (Fig. 3). 
DISCUSSION
Over the past few decades, several mechanisms have 
been reported in the development and maintenance of 
devastating neuropathic pain. It has been generally 
accepted that neuropathic pain arises due to lesions or 
dysfunctions in either the peripheral nerve system (PNS) 
or CNS. The pivotal mechanisms in the CNS are central 
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sensitization as well as a loss or dysfunction of the 
inhibitory control of spinal GABAergic and glycinergic 
interneurons.1-4) Central sensitization is initiated by exces-
sive glutamate release and activation of the NMDA 
receptor. This is followed by a triggering of the NOS 
cascade and subsequent gene expression due to Ca2＋ 
influx, resulting in long-term potentiation changes in 
synaptic transmission between nociceptive C-fibers and 
secondary projection neurons. An important sequela of 
nerve injury and other nervous system diseases is apoptosis 
of neurons in the PNS and CNS. Apoptotic neural death 
seems to induce neuronal sensitization and loss of inhibitory 
systems, and these irreversible processes and pathologic 
pain might be prevented by preemptive MK-801 in animal 
neuropathic pain models.1,17)
Until now, there has been much controversy regarding 
the cause of neuropathic pain. Some workers believe 
significant loss of GABAergic boutonnieres occurring at 
the denervated area after peripheral nerve injury are 
implicated,18-20) whilst others have speculated that decreased 
dorsal horn levels of the GABA synthesizing enzyme are 
responsible.17,21,22) Although the above controversy focused 
on the morphological changes in the dorsal horn, the belief 
that functional synaptic disinhibition involved distinct 
mechanisms of both inflammatory pain and neuropathic 
pain has remained constant. The central component of 
inflammatory pain sensitization is caused by PGE2 
mediated reduction in glycinergic neurotransmission. PGE2 
synthesized by inflammation induced cyclooxygenase2 
activates postsynaptic EP2 receptor. Once activated, EP2 
receptor then down regulates the activation of G-protein 
that triggers cAMP and PKA which is responsible for the 
phosphorylation and inhibition of the alpha3 subunit of the 
glycine receptor (Gly Rα3).3) On the other hand, microglia 
induces the disinhibition of GABA/Glycine interneurons. 
That is, microglia releases BDNF which down-regulates 
KCC-2 expression which then diminishes the trans- 
embrane Cl- gradient. The net effect of this is that the 
GABAergic and glycinergic input is rendered less inhibitory 
i.e. more excitatory.3.23,24)
In this our study, treatment with IT BIC (10μg) resulted 
in a reproducible functional loss of GABAA receptor 
activation and induced significant TEA which resembled 
the clinical phenomenon observed in neuropathic pain 
patients suffering from tactile allodynia.4-8) GABAA may 
modulate responses to an innocuous tactile stimuli via their 
action as inhibitory neurotransmitters at pre- and post- 
synaptic sites in the dorsal horn of the spinal cord.6,7) The 
disinhibition of presynaptic glutamate release, the 
postsynaptic NMDA receptor-NOS pathway4-8,25) and 
activated microglia (which releases mediators such as 
cytokines, PGE2, BDNF and NO) mediated modulation is 
crucial in inducing tactile allodynia.3,26)
In CNS neurons, agmatine is packaged into synaptic 
vesicles which are released upon neuronal depolarization. 
Initially, agmatine was conceptualized as synaptic vesicles 
containing an endogenous substance that acted to displace 
clonidine onf imidazoline receptors. However, agmatine 
has now been established to have affinity for several 
transmembrane receptors, such as alpha2-adrenergic, imi-
dazoline and NMDA receptors.9) Our in vivo study esta-
blished an antagonistic effect for agmatine on NMDA re-
ceptors which is in agreement with other in vitro 
studies.9,11) In addition to activity at these receptors, 
agmatine irreversibly inhibits neuronal NOS and down- 
regulates inducible NOS.9,27) The pharmacodynamic response 
to agmatine in NMDA-nociceptive behavior and thermal 
hyperalgesia tests showed that agmatine inhibits thermal 
hyperalgesia with significantly increased potency compared 
to nociceptive behavior, while MK-801 inhibits these 2 
responses with equal potency. These results suggest that 
agmatine has 2 sites of action.28)
Agmatine increased the neuropathic pain threshold 
through an effect that may involve the reduction of NO 
levels and noradrenergic activity in the brain.14) An 
increased number of large stellate or elongated somata in 
deep lamina III-V of the L5 segment expressed high 
neuronal NOS immunoreactivity. These results indicated 
that marked alterations of neuronal NOS in the spinal cord 
may contribute to spinal sensory processing as well as to 
development of neuronal plasticity phenomena in the 
dorsal horn.29) Both systemically and spinally administered 
agmatine produced marked antinociception, and further-
more interacted with glutamate receptors, namely NMDA 
and metabotropic NMDA-ionotropic receptors.10)
However several reports found that NOS is not related 
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to allodynia in neuropathic pain models.30,31) Lee et al.30) 
reported that a potent neuronal NOS inhibitor did not 
reduce mechanical sensitivity in spinal nerve ligated rats, 
and that neither the anti-allodynic nor the preemptive 
effects of L-NAME were mediated by NOS inhibition. 
Additionally, Karadag et al.31) reported that agmatine reduced 
mechanical allodynia at high doses, but that MK-801 and 
the NOS inhibitors, such as N(G)-nitro-L-arginine methyl 
ester and 7-nitroindazole, did not influence the antiallo-
dynic effects of agmatine. These results suggest that agmatine 
has a non-neuronal action site. Abe et al.32) reported that 
agmatine suppressed NO production in microglia. Neuronal 
death induced by microglia-derived NO was significantly 
attenuated in the presence of agmatine, which suggests that 
agmatine works to protect neurons by inhibiting production 
of NO in microglia.32,33) Agmatine also has neuroprotective 
effects against hypoxia-induced retinal ganglion cell 
damage through the JNK and NF-κB signaling 
pathways.34) This result suggests that agmatine could 
inactivate intra-microglial mitogen-activated protein kinase 
which activates microglial secretion of potentially 
neurotoxic mediators including proinflammatory cytokines, 
NO, BDNF and PGE2.
In contrast to the pharmacokinetic results, agmatine action 
on the pain behaviors had a duration of only 10 to 30 min. 
Such results suggested the existence of a currently unde-
fined agmatinergic extracellular clearance process in the 
spinal cord.15) In the present study, agmatine significantly 
attenuated BIC-induced tactile allodynia for 25 min which 
showed similar pharmacokinetic effects to the above men-
tioned reports.
We suggest that BIC induces the functional loss of 
GABAA receptors which results in excessive pre-synaptic 
glutamate release and activation of post-synaptic NMDA 
receptors. Agmatine, exogenously administered to the BIC- 
induced allodynia rat model, decreased TEA significantly, 
an effect mediated through its inhibitory actions on either 
neuronal NMDA receptor or NOS pathway. In addition, 
spinal microglia might facilitate the development of 
BIC-induced tactile allodynia. However, further studies are 
needed to reveal the neuroglial interactions involved in the 
mechanisms of BIC-induced allodynia. Agmatine might 
represent a viable treatment choice for neuropathic pain In 
a clinical situation where there is no commercially avail-
able NMDA receptor antagonist or microglial inhibitor.
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